Spectral Medical, based in Toronto, develops treatments for septic shock using its Endotoxin Activity Assay and Toraymyxin device, approved in Japan and Europe, with over 340,000 patients treated. The company also manufactures proprietary reagents and recombinant proteins for research and diagnostics.